This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this study is to define and describe the toxicities of oral valproic acid (VPA) administered twice daily at doses required to maintain serum trough concentrations of 100-150 mcg/ml or 150-200 mcg/ml in children with recurrent or refractory solid tumors, including CNS tumors. The secondary aims are: 1) To measure the steady state of serum trough concentration of free VPA at targeted total trough VPA concentraion. 2) To evaluate the pharmacokinetic profile of twice daily VPA administration in children. 3) To evaluate the steady state histone acetylation status of peripheral blood monocytes at the targeted trough VPA concentrations. 4) To investigate potential correlations between histone acetylation and free or total VPA trough concentrations. 5) To preliminary define the antitumor activity of VPA within the confines of a Phase 1 trial.
Showing the most recent 10 out of 203 publications
